• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
"The invisible": Participant's experiences in clinical trials.“隐形人”:参与者在临床试验中的经历
Perspect Clin Res. 2017 Jan-Mar;8(1):5-10. doi: 10.4103/2229-3485.198550.
2
Comparable indicators of therapeutic misconception between epilepsy or Parkinson's disease patients between those with clinical trial experience and trial non-participants.比较有临床试验经验和无临床试验经验的癫痫或帕金森病患者在治疗误解方面的可比指标。
Seizure. 2018 Aug;60:61-67. doi: 10.1016/j.seizure.2018.06.006. Epub 2018 Jun 9.
3
The ethical challenges raised in the design and conduct of pragmatic trials: an interview study with key stakeholders.实用临床试验设计和实施中引发的伦理挑战:关键利益攸关方的访谈研究。
Trials. 2019 Dec 23;20(1):765. doi: 10.1186/s13063-019-3899-x.
4
American Society of Clinical Oncology policy statement: oversight of clinical research.美国临床肿瘤学会政策声明:临床研究监督
J Clin Oncol. 2003 Jun 15;21(12):2377-86. doi: 10.1200/JCO.2003.04.026. Epub 2003 Apr 29.
5
Inadequacy of ethical conduct and reporting of stepped wedge cluster randomized trials: Results from a systematic review.阶梯楔形整群随机试验的伦理行为及报告存在不足:一项系统评价的结果
Clin Trials. 2017 Aug;14(4):333-341. doi: 10.1177/1740774517703057. Epub 2017 Apr 8.
6
A study of practical parameters and their relative importance as perceived by various stakeholders in clinical trials.一项关于临床试验中各种利益相关者所感知的实际参数及其相对重要性的研究。
J Young Pharm. 2011 Jan;3(1):60-4. doi: 10.4103/0975-1483.76421.
7
Ethical aspects of participation in the database of genotypes and phenotypes of the National Center for Biotechnology Information: the Cancer and Leukemia Group B Experience.参与国家生物技术信息中心基因型和表型数据库的伦理方面:癌症和白血病小组 B 的经验。
Cancer. 2012 Oct 15;118(20):5060-8. doi: 10.1002/cncr.27515. Epub 2012 Mar 13.
8
Response of religious groups to HIV/AIDS as a sexually transmitted infection in Trinidad.特立尼达宗教团体对作为性传播感染的艾滋病毒/艾滋病的应对措施。
BMC Public Health. 2005 Nov 16;5:121. doi: 10.1186/1471-2458-5-121.
9
10
Home nursing in clinical trials: Result from semi-structured qualitative interviews.临床试验中的家庭护理:半结构化定性访谈结果
Perspect Clin Res. 2024 Apr-Jun;15(2):94-98. doi: 10.4103/picr.picr_218_22. Epub 2023 Dec 6.

引用本文的文献

1
Conduct of cancer clinical trials: a qualitative study reporting views of patients, caregivers, public and clinical researchers.癌症临床试验的开展:一项报告患者、护理人员、公众和临床研究人员观点的定性研究
Ecancermedicalscience. 2025 Jul 22;19:1950. doi: 10.3332/ecancer.2025.1950. eCollection 2025.
2
What empirical research has been undertaken on the ethics of clinical research in India? A systematic scoping review and narrative synthesis.在印度,临床研究伦理方面开展了哪些实证研究?系统范围界定审查和叙述性综合。
BMJ Glob Health. 2021 May;6(5). doi: 10.1136/bmjgh-2020-004729.
3
Factors that impact on recruitment to randomised trials in health care: a qualitative evidence synthesis.影响医疗保健领域随机试验招募的因素:一项定性证据综合分析
Cochrane Database Syst Rev. 2020 Oct 7;10(10):MR000045. doi: 10.1002/14651858.MR000045.pub2.
4
Future of Indian clinical trials: Moving forward from hyped potential to human protection.印度临床试验的未来:从被过度炒作的潜力迈向对人类的保护。
Perspect Clin Res. 2017 Jan-Mar;8(1):2-4. doi: 10.4103/2229-3485.198553.

本文引用的文献

1
Consent for audio-video recording of informed consent process in rural South India.印度南部农村地区知情同意过程的音频-视频录制同意书。
Perspect Clin Res. 2015 Jul-Sep;6(3):159-62. doi: 10.4103/2229-3485.159941.
2
"Ready-to-Recruit" or "Ready-to-Consent" Populations?: Informed Consent and the Limits of Subject Autonomy.“随时可招募”还是“随时可同意”人群?:知情同意与受试者自主性的限度
Qual Inq. 2007 Sep;13(6):875-894. doi: 10.1177/1077800407304460.

“隐形人”:参与者在临床试验中的经历

"The invisible": Participant's experiences in clinical trials.

作者信息

Nadimpally Sarojini, Bhagianadh Divya

机构信息

Sama Resource Group for Women and Health, New Delhi, India.

出版信息

Perspect Clin Res. 2017 Jan-Mar;8(1):5-10. doi: 10.4103/2229-3485.198550.

DOI:10.4103/2229-3485.198550
PMID:28194331
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC5299806/
Abstract

BACKGROUND

The paper discussing the perspectives of clinical trial participants about the various aspects of CTs is based on the primary research conducted by Sama in 2012-13.

METHODOLOGY

In-depth interviews were conducted with 36 CT participants from the states of New Delhi, Gujarat, Maharashtra and Andhra Pradesh. In addition to CT participants, other key informants including investigators, representatives of Contract Research Organizations (CROs), sponsor, Ethics Committee (EC) members etc. were also interviewed to develop a comprehensive understanding of the functioning of the CT sector.

FINDINGS AND DISCUSSION

The paper describes the perspectives of participants on the relevant aspects of recruitment into CTs, reasons for participation in CTs, informed consent, adverse events and compensation. The role played by the push and pull factors in recruitment, the information asymmetry, the power imbalance between the health-care provider and seeker, the role of sociocultural factors, etc., are explored in the paper. Combined with the insights from other stakeholders, the study gives an understanding about the chasm between regulations and realities in the Indian CT sector. Further, the paper briefly explores the recent changes and amendments in the laws governing the CT sector that is aimed at improving the conduct of CTs and uphold the rights of participants.

CONCLUSION

Participants are the most important stakeholders in a CT setting. It is imperative that their voices are heard and their rights upheld for the ethical conduct of CTs.

摘要

背景

本文讨论临床试验参与者对临床试验各个方面的看法,其基于萨马在2012 - 13年进行的初步研究。

方法

对来自新德里、古吉拉特邦、马哈拉施特拉邦和安得拉邦的36名临床试验参与者进行了深入访谈。除了临床试验参与者,还采访了其他关键信息提供者,包括研究者、合同研究组织(CRO)代表、申办方、伦理委员会(EC)成员等,以全面了解临床试验领域的运作情况。

研究结果与讨论

本文描述了参与者对临床试验招募的相关方面、参与临床试验的原因、知情同意、不良事件和补偿的看法。文中探讨了招募过程中推动和拉动因素所起的作用、信息不对称、医疗服务提供者与寻求者之间的权力不平衡、社会文化因素的作用等。结合其他利益相关者的见解,该研究揭示了印度临床试验领域法规与现实之间的差距。此外,本文简要探讨了近期临床试验领域相关法律的变化和修订,这些旨在改善临床试验的开展并维护参与者的权利。

结论

参与者是临床试验环境中最重要的利益相关者。必须倾听他们的声音并维护他们的权利,以确保临床试验符合伦理规范。